Insmed (NSM) Doses First Patient in ARIKACE Phase 2
Tweet Send to a Friend
Up)
Insmed Incorporated (Nasdaq: INSM), announced that the first patient has been dosed in the Company's U.S. phase 2 clinical study of ARIKACE® (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacterial (NTM) lung disease entitled TARGET-NTM (Treatment with ARIKACE to Realize Greater Efficacy Trial).
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Wedbush Expects Positive Results from Insmed (INSM) ARIKAC Trial
- VIVUS, Inc. (VVUS) to Make Several Scientific Presentations in May
- Unusual 11 Mid-Day Movers 05/22: (CLNT) (MBND) (ZLC) Higher; (STP) (LDK) (FXEN) Lower
Create E-mail Alert Related Categories
Corporate News, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
